Business Wire

CA-TETRATE

5.1.2022 14:09:05 CET | Business Wire | Press release

Share
Tetrate and Federal Agency NIST Cohost ZTA and DevSecOps Conference 2022 Kicking Off With Istio and Envoy Training

Tetrate, the leading company providing a zero-trust application connectivity platform, announced their third annual conference on Zero Trust Architecture (ZTA) and DevSecOps for Cloud Native Applications in partnership with the U.S. National Institute of Standards and Technology (NIST), the federal organization responsible for creating security standards. The NIST–Tetrate multi-cloud conference is a premier event for CISOs, platform architects, and tech leadership from federal and corporate organizations.

The virtual conference will take place on January 27 from 8:00 a.m. – 5:00 p.m. EST and will be preceded by a 2.5-hour training on January 26, showcasing the implementation of Zero Trust Architecture on an actual Platform One deployment. This year’s conference will focus on DevSecOps and ZTA as foundational approaches to developing, deploying, and operating high assurance, cloud native applications. Featured speakers include: André Mendes , Department of Commerce CIO; Kelsey Hightower , Principal Engineer Google Cloud; Ronald Ross , NIST Fellow; and Zack Butcher , Tetrate Founding Engineer. The conference has seen tremendous growth in attendance over the past three years. Past speakers have included Nicolas Chalain , the U.S. Air Force’s first Chief Software Officer, and Zulfikar Ramzan , CTO of RSA Security.

“Cybersecurity incidents are one of the biggest issues facing organizations today, especially as the world moves towards cloud-native applications,” said David Ferraiolo of NIST. “Developing, deploying, and operating zero-trust enabled applications to achieve security, reliability, and resiliency is extremely important for organizations to feel secure.”

“Over the last three years, the NIST–Tetrate conference has featured dialogues and workshops from the world’s most esteemed service mesh and cybersecurity experts," said Varun Talwar, co-founder of Tetrate. "The growth in popularity of the conference is a testament to the importance of ZTA and DevSecOps in a multi-cloud environment. This year, again, we're thrilled to gather together and offer our global community valuable insights and perspectives from top visionaries."

Cloud-native applications often consist of microservices deployed across a combination of public cloud, private cloud, and on-prem, also known as heterogeneous infrastructure. This has created challenges related to connectivity, security, and reliability for delivering high-assurance applications, leading to the popularity of DevSecOps and ZTA. Service mesh plays a critical role in incorporating zero-trust design and DevSecOps principles by adding security and reliability to connect microservices across infrastructures without any additional code.

The conference will feature presentations by domain experts, practitioners, and thought leaders in DevSecOps and Zero Trust Architecture (ZTA) deployments, as well as demonstrations of proof-of-concept use cases in multi-cloud environments. Presentations will address the following:

  • ZTA guiding principles and approaches for workflow, system design, and operations through DevSecOps pipelines, authentication and authorization frameworks, and continuous monitoring;
  • NIST’s latest guidance on DevSecOps and security engineering practices;
  • The role of automation in operational security;
  • The benefits of prescribed approaches, such as prevention of configuration drift and continuous authority to operate.

In addition to a lineup of notable speakers, the training on January 26 will help deliver an educational experience where attendees will learn new skills and cover the deployment of a zero-trust platform with the use of Istio, Kubernetes, and other tools to implement the following security components:

  • in-app and user-level security permissions,
  • encryption in transit,
  • enhanced identity and access controls, and
  • runtime observability.

Tetrate also provides free passes , on request, to application security professionals who need the $35 fee waived.

Join the virtual event: Registration page

  • Join and follow the conversation with hashtag #ZTACon2022 #DevSecOps
  • Twitter: @tetrateio
  • LinkedIn: Tetrate
  • YouTube: Tetrate

For more information regarding ZTA and DevSecOps Conference 2022, an entirely virtual experience taking place this week, please visit: https://www.tetrate.io/zta-devsecops-conference-2022 .

About Tetrate–NIST Collaboration

Tetrate and NIST have collaborated over the last three years across multiple deliverables. Using NIST’s experience with cybersecurity and Tetrate’s expertise on secure service mesh, they have collaborated to produce U.S. security standards for a distributed architecture:

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Customers get consistent, baked-in observability, runtime security, and traffic management in any environment. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .

About NIST

The National Institute of Standards and Technology (NIST ) was founded by the U.S. Congress in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials, and computer chips, innumerable products and services today rely in some way on technology, measurement, and standards provided by NIST.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye